Table 1. Characterization of blast cells derived from bone marrow aspirate of the ALGs/B-ALL patient.
| SSC/CD19+ | ALGS patient | VR-ALL | RS4;11 | SUP-B15 |
|---|---|---|---|---|
| CD10 | ++ | ++ | - | +++ |
| CD13 | - | +/− | - | - |
| CD15 | +/− | + | +++ | + |
| CD20 | + | + | - | + |
| CD22 | ++ | ++ | +++ | +++ |
| CD33 | + | + | + | - |
| CD34 | ++ | + | - | +++ |
| CD38 | ++ | + | ++ | ++ |
| CD45 | + | + | ++ | - |
| CD58 | ++ | + | ++ | + |
| CD66c | ++ | - | - | - |
| CD133 | - | na | na | na |
| cyCD79a | ++ | + | - | + |
| cyIgμ | - | + | - | + |
| cytCD3 | - | na | na | na |
| MPO | - | - | - | - |
| NG2 | - | + | - | - |
| TdT | + | + | + | + |
Flow cytometry analysis of patient's blast cells using fluorescent conjugated antibodies specific to extracellular or/and intracellular protein markers. For each antibody, the mean of fluorescence was normalized to the mean of fluorescence obtained with its specific isotype conjugated to the same fluorescent marker. “na”: not available.